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February 2013 in 2 additional clinical cohorts, the Finnish Cardiovascular Study (FINCAVAS) 8 and the Angiography and Genes Study (ANGES). 9 Meta-analyses of the association between the top hits and cardiovascular outcomes were carried out on 3 independent cohorts (FINCAVAS, ANGES, and LURIC; KORA did not have angiographic data).
The current study comprises 8244 subjects with measured early subclinical (YFS) or more advanced atherosclerosisrelated clinical phenotypes, that is, cardiovascular disease endpoints (FINCAVAS, ANGES, KORA, and LURIC). The mentioned studies were engaged in cooperation with the ongoing AtheroRemo Consortium and have been widely involved with other international genetic consortia (onlineonly Data Supplement references).
Materials and Methods
For more details, please see the online-only Data Supplement.
Study Populations and Ethical Statements
All studies were conducted according to the guidelines of the Declaration of Helsinki, and the study protocols were approved by local ethics committees. All participants gave an informed consent.
The YFS cohort is a Finnish longitudinal population study sample on the evolution of cardiovascular risk factors from childhood to adulthood. 4 The first cross-sectional study was conducted in 1980 at 5 different centers. These subjects were reexamined in 1983 and 1986 as young individuals and in 2001 and 2007 as adults. In the current study, we used the variables measured in 2001. Genotype, risk factor, and phenotype data were available for 2080 subjects, and they formed the current study population.
The LURIC study comprises 3316 white patients who were referred to coronary angiography due to chest pain at a tertiary care center in Southwest Germany between 1997 and 2000. 5 All the necessary covariate and endpoint data were available for 2912 LURIC patients, who were hence included in the present study.
The Monitoring Trends and Determinants in Cardiovascular Disease/KORA Augsburg study (KORA) is a series of populationbased surveys conducted in the region of Augsburg in Southern Germany. 7 The data for the current study were drawn from a subcohort randomly selected on the basis of sex and survey from the KORA surveys S1-S3 conducted between 1984 and 1995. 6 Of these, 1326 subjects had all the required covariate and end point data available and were included in the current study.
The FINCAVAS population consists of patients who underwent an exercise stress test at Tampere University Hospital, Finland. 8 From the overall recruited study population, 1118 individuals had all the necessary angiographic, genetic, and covariate data available and were included in the current study.
The ANGES population consisted of 1000 patients with a symptomatic heart disease referred to as coronary angiography to rule out or confirm coronary artery disease (CAD). 9, 10 Angiographic, genetic, and covariate data were available for 808 individuals (online-only Data Supplement Table I , and section A1).
Clinical and Biochemical Characteristics of the Participating Study Cohorts

OxLDL, Lipoprotein, and Apolipoprotein B Measurements
In YFS, LURIC, and KORA, the circulating oxLDL levels were measured using the same immunoassay. In brief, circulating serum oxLDL levels were assayed with a competitive ELISA utilizing a specific murine monoclonal antibody, mAB 4E6 11 (Mercodia, Uppsala, Sweden; detection limit <0.3 U/L).
In YFS, LDL baseline diene conjugation was measured by determining the level of baseline diene conjugation in lipids extracted from LDL. 12 In all cohorts, standard methods were used for serum cholesterol and apolipoprotein B (apoB) analyses (online-only Data Supplement section A2).
Cardiovascular Endpoint Definitions in FINCAVAS, ANGES, and LURIC
Angiographically Verified CAD
In FINCAVAS, ANGES, and LURIC, coronary angiography (KORA did not have angiographic data) was performed using the standard Judkins technique. Transluminal narrowing of at least 50% in any major coronary artery (left anterior descending, left circumflex, or right coronary artery) was the criterion for the diagnosis of CAD. The number of arteries with significant >50% stenosis was used to determine the severity of CAD. In this study, subjects with no CAD were compared with those with 3-vessel disease.
Myocardial Infarction
In LURIC, myocardial infarction (MI) was defined as evidence of any MI (acute, previous, ST-elevation MI, or non-ST-elevation MI). 5 In FINCAVAS, a history of prior MI was based on patient interviews, resting ECG recordings, and hospital records. 8 In ANGES, the clinical diagnosis of MI was based on symptoms, electrocardiographic findings, and biochemical marker tests measuring troponin I and creatine kinase (online-only Data Supplement section A3). 9 
Genotyping and Quality Control in the Different Cohorts
In brief, in YFS, genotyping was carried out by using a custombuilt Illumina Human 670k BeadChip at the Welcome Trust Sanger Institute. Genotype imputation was performed using MACH 1.0 13 and HapMap II CEU (release 22, NCBI build 36, dbSNP 126) samples as a reference. After imputation, 2 543 887 SNPs were available. SNPs with a squared correlation (r 2 ) of <0.30 between imputed and true genotypes were eliminated from the analysis.
In the FINCAVAS, ANGES, and LURIC cohorts, genotyping was performed by using the Metabochip, which is a custom Illumina iSelect genotyping array designed to test ≈200 000 SNPs identified through genome-wide meta-analyses for metabolic and atherosclerotic/ cardiovascular diseases and traits. In KORA, genotyping was accomplished by using the IBC 50K array, which is an Illumina iSelect genotyping array designed to test ≈50 000 SNPs identified through genome-wide meta-analyses associated with a range of cardiovascular, metabolic, and inflammatory syndromes. 14 The studied top SNP (rs676210) passed quality check (call rate >0.95, minor allele frequency >0.01, Hardy-Weinbert equilibrium P>10 -6 ) in all 3 cohorts (online-only Data Supplement, section A4).
Statistical Analyses
For the GWAS analysis, oxLDL was Box-Cox transformed. Residuals were obtained using a linear regression model in which the variables were adjusted for sex, age, and body mass index, as well as principal components (to control population stratification) 15 and apoB. Tests for additive genetic effects were carried out on a linear scale by means of linear regression. Genotypes were coded as 0, 1, or 2 when the SNP was genotyped and by dosage (scale 0-2) when imputed. In true genotyped SNPs, the minor allele was the effect allele. The imputation software (MACH 1.0) used HapMap II as reference to assign the alleles for imputed SNPs. Tests were performed to assess the association of SNPs with the standardized residuals using PLINK 16 for the genotyped data. ProbABEL 17 was employed to fit the linear regression model, taking into account the genotype uncertainty in imputed SNPs. P values were combined from the analysis by favoring genotyped SNPs over imputed ones. Quartile-quartile and Manhattan plots were drawn for the analysis of the results. The P value for genome-wide significance was set at P<5×10 −8 , corresponding to a target α of 0.05 with a Bonferroni correction for 1 million independent tests.performed using the R Statistical package v. 2.11.1 (http://www.rproject.org). To define associations nonredundantly associated with oxLDL, we applied a forward-selection algorithm. 19 We associated the SNPs with genome-wide significance (top SNPs) with cardiovascular-disease-related endpoints (angioraphically verified CAD, severity of CAD, and MI) in FINCAVAS, ANGES, and LURIC. The associations were assessed using the appropriate statistical models (χ 2 test, ANOVA, linear regression, or Cox Proportional-Hazards regression) in R. Meta-analyses were performed using a fixed effects model when the P for cohort heterogeneity was >0.05. KORA did not have angiographic data and was only used for the replication of the oxLDL association. The YFS participants were young (<39 years of age, average age 31.7 years in 2001), still without major clinical endpoints, and it was therefore not possible to include them in these analyses. P<0.05 were considered significant (online-only Data Supplement, section A5).
Results
General Characteristics of the Study Populations
There was a predominance of women in the YFS population and a predominance of men in the FINCAVAS, LURIC, and KORA populations (online-only Data Supplement Table I ). Furthermore, age differences existed between the cohorts, with YFS as the youngest and LURIC as the oldest population. The mean oxLDL levels also varied, being highest in KORA and lowest in LURIC (online-only Data Supplement Tables I and II) .
GWAS Analysis of Oxidized LDL Pinpoints a Novel Variant Affecting LDL Oxidation
In the YFS discovery GWAS, 328 SNPs were associated with oxLDL with genome-wide statistical significance (P<5×10 -8 ). All statistical adjustments applied produced identical top SNP associations. All of these SNPs were within 210 kb from the apoB-100 precursor coding region (OMIM 107730) on chromosome 2 (see the quartile-quartile plot [online-only Data Supplement Figure Using a forward-selection algorithm with a P value cut-off of 5×10 -8 , only 1 SNP (rs676210) was independently associated with oxLDL, implicating a role as the proxy for all of the associations. Eleven SNPs had r 2 >0.5 with rs676210 (rs1042034, rs6728178, rs6754295, rs673548, rs6711016, rs11902417, rs10184054, rs6544366, rs4564803, rs7557067, and rs2678379), and forward-selection algorithm cannot separate, which is the true proxy. We chose to include rs676210 in the subsequent analyses because it is biologically most plausible from its linkage disequilibrium-block and also because it causes a missense mutation. We also ran the GWAS by adjusting for rs676210, in addition to other covariates. No other independent associations were found (online-only Data Supplement Figure III) . Moreover, in a haplotype analysis of all associated missense mutations, only rs676210 (or rs1042034, which is in perfect linkage disequilibrium with rs676210) showed an independent effect on oxLDL.
Structural Testing of the Pro2739Leu (rs676210) and Other Related Missense Variants
The variant rs676210 causes a missense mutation (change of proline to leucine at position 2739) in apoB. This mutation was predicted to be damaging in the analysis performed with the PolyPhen-2 software. This supports the notion of the biological functionality of the amino acid change caused by the SNP. The SNP in perfect linkage disequilibrium with rs676210 (rs1042034 [Ser4338Asn]) was predicted to be benign, which further supports the role of rs676210 as the functional variant. Two other nearby missense mutations (rs533617 [His1923Arg] and rs679899 [Ala618Val]) were also predicted to be probably damaging to apoB but showed no independent effect on oxLDL in the haplotype analyses and were, therefore, not studied further. The other significantly associated missense mutations (rs1801695 [Ala4481Thr], rs1367117 [Thr98Ile], and rs1042031 [Glu4181Lys]) were predicted to be benign and did not show independent effect on oxLDL in the haplotype analyses. As rs676210 was the most probable SNP behind all the found associations, further analyses were conducted with this SNP only. In YFS, rs676210 was associated with oxLDL with a P value of 4.3×10 -136 and an effect size of 13.2 U/L oxLDL per allele. The major (risk) allele carriers had significantly higher levels of oxLDL (Table 1 ). In addition to conventional risk factors, rs676210 explained 11% of the variation in oxLDL (r 2 =0.11). The association was replicated in 2 independent cohorts, in LURIC with a P value of 2.5×10 -47 and an effect size of 10.5 U/L, and in KORA with a P value of 1.1×10 -11 and an effect size of 7.8 U/L. The association was also strong with the oxLDL/ LDL, oxLDL/apoB, and oxLDL/LDL-apoB ratios (Table 1) .
In a linear regression model adjusted for age, sex, and body mass index in the YFS, rs676210 also associated significantly with the apoB-epitope-structure-independent measurement of oxLDL, LDL diene conjugation, with a P value of 0.028 and an effect size of 0.73 µmol/L, confirming the effect of the studied SNP on LDL oxidation.
Furthermore, rs676210 was significantly associated with apoB in YFS: with triglyceride concentrations in YFS and LURIC; with very-low-density lipoprotein (VLDL) cholesterol concentration in LURIC; with high-density lipoprotein (HDL) cholesterol concentrations in YFS, LURIC, and KORA; and with total cholesterol/HDL cholesterol concentrations in YFS and LURIC (Tables 1).
Meta-Analyses of the Association Between the apoB Pro2739Leu (rs676210) Mutation and Cardiovascular Outcomes
We found statistically significant differences in traits between genotypes in the angiographic cohorts (FINCAVAS, ANGES, and LURIC; see Tables 1 and 2 ). Therefore, and because of the pleiotropic effect of rs676210 with lipids, the meta-analyses were performed adjusting for age, sex, body mass index, LDL, HDL, and triglycerides ( Figure 2) . We also performed the analyses without adjusting for LDL, HDL, and triglycerides to see what proportion of the effects is caused by the pleiotropic effects of rs676210 (online-only Data Supplement Figure IV) .
The apoB Pro2739Leu (rs676210 allele G, also the allele causing high oxLDL levels) was not associated with CAD, 3-vessel CAD, or MI after adjustment for age, sex, body mass index, statin use, LDL, HDL, and triglycerides ( Figure 2) . Results without adjustment for LDL, HDL, and triglycerides were also not significant in the meta-analysis (online-only Data Supplement Figure IV) .
Discussion
Of the 328 SNPs associated with circulating oxLDL levels in a healthy white adult population (YFS), only 1 missense mutation leading to a proline-to-leucine interchange in apoB (SNP rs676210, Pro2739Leu) on chromosome 2 remained significant in further analysis. The association of apoB rs676210 with oxLDL was convincingly replicated in the LURIC and KORA cohorts. We also tested the association of rs676210 with cardiovascular endpoints in a meta-analysis of 3 independent clinical cohorts but did not find significant associations.
The YFS subjects had higher mean oxLDL levels than the LURIC subjects, although the LURIC subjects were older and had more comorbidities. This could simply be due to different storage conditions or differences in the use of statin medication 21 or the levels of oxidants or antioxidants. In LURIC, there was a higher proportion of statin users in comparison with the healthier YFS population (mean oxLDL levels were lower among statin users than among nonusers; data not shown).
There are few previous reports about the genetics of LDL oxidation. To our knowledge, ours is the first GWAS on circulating oxLDL. Employing a forward-selection algorithm, performing haplotype analyses, assessing the damage-producing probability of the SNPs, and running the GWAS with top-SNP adjustment strongly suggest that apoB rs676210 is the most probable functional variant and the proxy for all of the found 328 associations.
Each LDL particle contains 1 apoB moiety. In the current study, the missense mutation of proline to leucine (rs676210, Pro2739Leu) in apoB increased plasma oxLDL levels in a step-wise manner in the genotype order of AA (Leu/Leu, the minor allele), GA (Pro/Leu), and GG (Pro/Pro). Our results are supported by the fact that the variation in apoB probably changes the 3-dimensional structure of apoB 22 in a way that makes LDL less prone to oxidation in homozygous apoB (Leu/Leu) minor allele carriers.
There seem to be some pleiotropic effects for this variation as rs676210 was also associated with HDL cholesterol in all 3 cohorts and with triglyceride levels in YFS and LURIC. The oxLDL association, however, was adjusted for these, so the main effect seems to be on the oxLDL levels.
There are a few studies related to the genetic variation rs676210. In a previous study, the rs676210 minor allele (A) was associated with lower triglyceride, total cholesterol, and LDL cholesterol levels and with higher HDL cholesterol levels, with a P<5×10 −8 , in comparison with major allele (G) carriers. 23 These results are in accordance with our study. In another earlier report, rs676210 was found to associate with VLDL-related fractions, triglycerides, and mean VLDL/LDL size. 24 In that study, minor allele carriers had larger VLDL/ LDL particles and lower VLDL cholesterol and triglyceride concentrations. These findings are also in accordance with our results, showing a linear trend for the minor allele carriers in LURIC to have lower VLDL cholesterol levels (P=0.0034). VLDL cholesterol was not measured in YFS with this method.
Interestingly, the minor allele of rs676210 (A) has been linked to an improved response to fenofibrate treatment, 25 the treatment was reported to lower triglyceride levels by 24.7%, 28.3%, and 34.5% according to the rs676210 genotypes GG, GA, and AA, respectively. The allele found to decrease LDL oxidation also seems to improve the response to fenofibrate. Furthermore, minor allele carriers had lower triglyceride levels in YFS and LURIC when compared with major risk allele carriers. We do not have data on fenofibrate use in our cohorts.
It seems that the oxLDL levels associated apoB Pro2739Leu mutation is not associated with cardiovascular endpoints. This was observed across the cohorts studied in the combined meta-analysis. The association of serum oxLDL levels measured with Mercodia ELISA assay with CAD is controversial. Many smaller studies report oxLDL as a predictor of CAD; however, larger studies have been negative after adjusting for standard lipid variables. 26 Our results are in line with these larger nongenetic studies by showing that serum oxLDL levels associated gene variant is not associated with the cardiovascular endpoints.
Limitations and Strengths of the Study
A strength of the study is the replication of the major results in multiple independent cohorts. The association of rs676210 with LDL oxidation is convincing. The oxidation of LDL was, however, measured by structural changes in the apoB protein and does not fully account for the lipid component of these apoB-containing particles. To confirm that our results are not due to the possibility of the Pro2739Leu substitution altering the binding of the used monoclonal antibody to apoB, we also applied a second, apoB-epitopestructure-independent assay to assess the effect of the SNP on the LDL oxidation, with parallel results. In this independent assay, the SNP rs676210 was significantly associated with LDL diene conjugation. These results put together show that our findings are not due to the oxLDL assay employed and imply a true biological function for rs676210 in LDL oxidation.
The step-wise algorithm and top-SNP-adjusted GWAS strongly suggest that rs676210 is the proxy SNP. We also carried out manual haplotype analyses, arriving at the same conclusion of rs676210 as the implied proxy. This information, together with the predicted damaging change caused in apoB (proline-to-leucine interchange), indicates that out of the available SNPs, this is the most likely functional top-SNP candidate. The SNP in perfect linkage disequilibrium with rs676210 was predicted to be benign. Two other nearby missense mutations were also predicted to be damaging but showed no independent effect in the haplotype analysis nor with the forward-selection algorithm; other associated missense mutations were predicted not to be damaging. These results strongly suggest that rs676210 is the true functional variant. However, it is important to note that the true proxy cannot be found with 100% certainty by means of bioinformatic methods, and, therefore, we performed the analyses with the most probable one.
The effect was studied only in whites and might not be generalizable to other populations. There were significant differences in sex distributions and mean ages between the cohorts. However, the association of rs676210 with oxLDL concentration remained significant despite these and other differences in the background populations.
In comparison, the cohorts used for the clinical endpoint association assessments were quite similar. The current analyses related to oxLDL did not include the FINCAVAS or ANGES study populations because oxLDL was not measured in them.
The clinical implications of rs676210 leading to Pro2739Leu missense mutation require further investigation. However, we did not find significant associations in a meta-analysis of 3 independent studies.
Conclusions
We found an SNP that is important in regulating oxLDL levels but not a major genetic factor for studied cardiovascular endpoints.
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CLINICAL PERSPECTIVE
Atherogenic oxidized low-density lipoprotein (LDL) is regarded as a key element in atherosclerosis. By performing a genome-wide association analysis, we identified the most important single-nucleotide polymorphism associating with circulating levels of oxidized LDL. The discovered single-nucleotide polymorphism (rs676210) leads to a Pro2739Leu missense mutation in the apolipoprotein B gene, likely rendering LDL less prone to oxidation and resulting in significantly lower levels of circulating oxidized LDL. Oxidized LDL levels have previously been reported to predict coronary artery disease but often not independently after adjusting for standard lipid variables. Correspondingly, we did not observe statistically significant associations between rs676210 and the age of onset of cardiovascular endpoints in a meta-analysis of 3 independent patient populations undergoing angiography (N=4801). However, population stratification by genetic and environmental factors regulating the oxidation of LDL could potentially lead to improved accuracy in patient selection for interventions such as statin therapy, novel antioxidant-molecule-based therapies, or diet-based prevention strategies. Supporting this, the discovered single-nucleotide polymorphism has previously been found to associate with an improved response to fenofibrate treatment, with the minor (protective) allele associating with greater reductions in triglyceride levels. Our study provides a useful framework for future investigations to elucidate the oxidative processes underlying coronary artery disease and to investigate how genes and environmental exposures (such as smoking) interact in causing the condition. 13 
Supplemental Material Supplementary introduction
Atherosclerosis, a major cause of disability and death, is a multifactorial disease with a strong hereditary and environmental background [1] [2] [3] .
The conversion of low-density lipoprotein (LDL) to oxidized LDL (oxLDL) increases the atherogenic potential of LDL and is regarded as a key event in the development of fatty streaks-the early atherosclerotic lesions [4] [5] [6] [7] [8] . OxLDL can be found in the macrophages in atherosclerotic lesions, but not in healthy arteries 9 . Macrophages do not take up oxLDL via the LDL receptor 10 , but instead via scavenger receptors [4] [5] [6] [7] [8] 11 . The binding of oxLDL to the scavenger receptors, and their subsequent internalization, is a key step in the accumulation of cholesterol in macrophages, which transforms them into lipid-laden foam cells 11 .
The mentioned studies were engaged in cooperation with the ongoing AtheroRemo Consortium 12 and have been widely involved with other international genetic consortia [13] [14] [15] [16] [17] [18] [19] .
A. Supplementary Materials and Methods
Detailed cohort descriptions
The Cardiovascular Risk in Young Finns Study (YFS)
The first cross-sectional study was conducted in 1980 at five different centers. 
The Finnish Cardiovascular study (FINCAVAS)
The exercise test indications were a diagnosis of CAD, a post-MI assessment, evaluation of drug therapy, arrhythmia, assessment of performance (working capacity), or an evaluation prior to surgery. The purpose of FINCAVAS is to construct a risk profile of individuals at high risk of cardiovascular diseases, events, and deaths. FINCAVAS has an extensive set of data on patient history, genetic variation (the Metabochip), cardiovascular parameters, ECG markers, and follow-up data on clinical events, hospitalizations, and deaths. Of the patients included, 43.6% also underwent coronary angiography. 21 
The Angiography and Genes Study (ANGES)
The population studied consists of 1,000 Finnish individuals participating in the ongoing ANGES study. Angiographic, genetic, and covariate data was available for 808 individuals (516 men and 292 women; mean age 62 ± 10). The data was collected between September 2002 and July 2005. All patients underwent coronary angiography at Tampere University Hospital due to clinically suspected coronary artery disease 22 . The study is a cross-sectional study, and after the angiography, patients were treated according to the Finnish Current Care
Guidelines. Patients were also interviewed by a study nurse, and a questionnaire was used to collect general information-age, sex, body mass index, alcohol consumption, smoking, medication as well as traditional risk factors of atherosclerosis and myocardial infarction (MI). The whole study has been approved by the Ethics Committee of Pirkanmaa Hospital District, and written informed consent was obtained from each patient. 22 
Other clinical and biochemical characteristics in more detail
Oxidized LDL, lipid, and apolipoprotein B (apoB) measurements
In the YFS, LURIC, and KORA, the circulating oxidized LDL levels were measured using the same immunoassay. In brief, circulating serum oxLDL levels were assayed with a competitive enzyme-linked immunosorbent assay (ELISA) utilizing a specific murine monoclonal antibody, mAB 4E6 23 (Mercodia, Uppsala, Sweden; detection limit < 0.3 U/l).
The monoclonal antibody is directed against a conformational epitope in the apoB-100 moiety of LDL that is generated by substituting at least 60 lysine residues of apolipoprotein B-100 with aldehydes. The substitute aldehydes can be produced by the peroxidation of LDL lipids, resulting in the generation of oxLDL. Aldehydes released by endothelial cells under oxidative stress or by activated platelets may also induce the oxidative modification of apolipoprotein B-100 in the absence of the peroxidation of LDL lipids 24 .
In YFS, LDL baseline diene conjugation was measured by determining the level of baseline diene conjugation in lipids extracted from LDL 25 . In brief, serum LDL was isolated by means of precipitation with buffered heparin. Lipids were extracted from LDL samples with chloroform-methanol, dried under nitrogen, then redissolved in cyclohexane and analyzed spectrophotometrically at 234 nm.
In YFS, LURIC, ANGES, and FINCAVAS, venous blood samples were drawn after an overnight fast. In KORA, non-fasting venous blood samples were drawn. Standard enzymatic methods were used for serum total cholesterol, triglycerides, and high-density lipoprotein (HDL) cholesterol. LDL cholesterol was calculated in YFS, KORA, ANGES, and FINCAVAS by the Friedewald formula: LDL cholesterol = total cholesterol -HDL cholesterol -triglyceride-concentration / 2.2 26 . In LURIC, lipoproteins were separated by means of a combined ultracentrifugation-precipitation method (ß-quantification) 27 .
In YFS, apoB was analyzed immunoturbidometrically (Orion Diagnostica, Espoo, Finland); the interassay CV was 2.8% for apoB 28 . In LURIC, apoB was analyzed with a photometric assay using an antihuman apoB antibody (apoB Test, Rolf Greiner Bio-chemica, Flacht, Germany). In LURIC, Individuals were classified as having diabetes mellitus if their plasma glucose level was > 125 mg/dL (7 mmol/l) in the fasting state or >200 mg/dL (11 mmol/l) 2 h after the oral glucose load (performed on individuals with no previous diabetes mellitus diagnosis), or if individuals were receiving oral antidiabetics or insulin.
In YFS, ANGES, and FINCAVAS
In all studies, hypertension was diagnosed if the systolic and/or diastolic blood pressure exceeded 140 and/or 90 mmHg, respectively, or if there was a significant history of hypertension (use of antihypertensive medication). and inter-assay coefficients of variation for quality control test sera were 4.0% and 12.0% for the IRMA assay, and 2.5% and 5.1% for the nephelometric assay.
In YFS, FINCAVAS, ANGES, and LURIC
Assessments of risk factors and medications
In all studies, body mass index (BMI) was calculated with the formula BMI = weight (kg)
In all studies, subjects were asked to fill out questionnaires that included questions concerning the use of medications (including lipid-lowering medication [statins]).
Cardiovascular endpoint determinations and definitions of different cohorts
Cardiovascular endpoints studied in the Ludwigshafen Risk and Cardiovascular Health
(LURIC) study.
Coronary artery disease (CAD) was assessed by angiography using the maximum luminal narrowing estimated by visual analysis 27 . Clinically relevant CAD was defined as the occurrence of at least one 50% stenosis in at least 1 of 15 coronary segments.
Cardiovascular endpoints studied in the Finnish Cardiovascular Study (FINCAVAS)
The presence of coronary artery disease (CAD) in the patients prior to the exercise test was determined based on patient interviews, resting ECG recordings, and existing hospital records 21 . Of the patients, 43.6% had undergone coronary angiography that unambiguously revealed the status of the coronary arteries. The data on the presence of hypertension, valvular conditions, cardiomyopathies, other heart diseases, and diabetes (types 1 and 2) were based on interviews and hospital records.
The Angiography and Genes Study (ANGES)
A clinical diagnosis of MI was based on symptoms, electrocardiographic findings, and biochemical marker tests measuring troponin I and creatinekinase. Information concerning previous cardiovascular diseases, surgical procedures, and MIs was collected from patient records at Tampere University Hospital. Coronary angiography was performed using the standard Judkins technique. Transluminal narrowing of at least 50% in any major coronary artery (left anterior descending, left circumflex, or right coronary artery) was the criterion for the diagnosis of coronary artery disease. 
Genotyping and quality control (QC) in the different cohorts
In YFS, genomic DNA was extracted from peripheral blood leukocytes using a commercially 
Statistical analyses in more detail
For the GWAS analysis, oxLDL was Box-Cox transformed. Residuals were obtained using a linear regression model in which the variables were adjusted for sex, age, and BMI, as well as principal components (to control population stratification 34 ) and apoB. The GWAS was adjusted for apoB to identify SNPs affecting the oxidation process only (each LDL particle has one apoB molecule and the measured oxLDL strongly correlates with apoB). A GWAS was also performed on oxLDL without adjusting for apoB as well as by adjusting for LDL concentrations. Residuals were standardized (mean 0, s.d. 1) and their distributions confirmed to be very close to normal by means of visual Q-Q plot analysis. We also verified that the estimates for the beta coefficients from the GWAS were not driven by a few outliers by plotting leverage versus standardized residuals plots for the residuals.
Tests for additive genetic effects were carried out on a linear scale by means of linear regression. Genotypes were coded as 0, 1, or 2 when the SNP was genotyped and by dosage (scale 0-2) when imputed. Tests were performed to assess the association of SNPs with the standardized residuals using PLINK 35 for the genotyped data. ProbABEL 36 was employed to fit the linear regression model, taking into account the genotype uncertainty in imputed SNPs.
P values were combined from the analysis by favoring genotyped SNPs over imputed ones.
Q-Q and Manhattan plots were drawn for the analysis of the results. The p value for genomewide significance was set at p < 5 × 10 −8 , corresponding to a target α of 0.05 with a
Bonferroni correction for one million independent tests.
The severity (functionality) of mutations was assessed by PolyPhen-2 version 2.1.0 software 37 .
Further statistical analyses were performed using the R Statistical package v. 2.11.1
(http://www.r-project.org). In order to define associations non-redundantly associated with oxLDL, we applied a forward selection algorithm (as described in 38 Abbreviations: n, number. *n for subjects having data required for the present study; †values expressed as means (standard deviations). 
